Providence Investment Company Limited
VC Fund
Germany, United States
Providence Investment Company Limited is a VC fund in Germany focused on Biotechnology and Biopharma. Providence Investment Company
- Total investments:
- 15
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Providence Investment Company Limited invests in
Stages Providence Investment Company Limited invests in
Countries Providence Investment Company Limited invests in
Round sizes
Round size
- Series B
- $2.2M–$30M
Investment Focus
Industry
- Biotechnology 5 (33%)
- Biopharma 3 (20%)
- Medical 2 (13%)
- Health Care 2 (13%)
- Life Science 2 (13%)
Stage
- Funding Round 4 (27%)
- Series A 2 (13%)
- Series B 2 (13%)
- Seed 1 (7%)
- Venture - Series Unknown 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cambridge Photon Technology is a developer of organic photovoltaic devices used to enhance next-generation solar technology. Its devices engage in the deployment of off-grid solar power and use advanced nanotechnology to split each incoming blue and green photon into two infra-red photons that enable clients to deploy solar power throughlightweight devices whenever needed. | $1.2M / Nov 06, 2025 | ||
| evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines. | $24.1M / Series B / Feb 07, 2023 | ||
| evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines. | $30M / Series B / Mar 02, 2020 | ||
| evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniqueswe are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines. | $12.3M / Series A / Jan 30, 2018 | ||
| DefiniGEN was acquired by Pixl Bio AB in July 2025. DefiniGEN was founded in April 2012 to industrialize the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. The company has world-leading expertise in the area of iPSC production and metabolic disease modelling. The application of these technologies in drugdiscovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments. In addition the technology platform utilises fully defined and humanized conditions required for the development of regenerative medicine cellular therapies.DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke’s Hospital and in addition has in-licensed the Yamanka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc. | $2.2M / Series B / May 23, 2016 | ||
| CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | Venture - Series Unknown / Oct 19, 2015 | ||
| CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $5.6M / Jun 25, 2013 | ||
| Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated acatalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline. | $8.8M / Jun 03, 2013 | ||
| Phico Therapeutics is a biotechnology company developing a novel platform technology which it believes could form the basis for a new generation of antibiotics to overcome antibacterial resistance. | $1.3M / Jan 01, 2009 | ||
| CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $4.3M / Oct 02, 2007 | ||
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Providence Investment Company Limited invest in?
Providence Investment Company Limited invests primarily in Biotechnology, Biopharma and Medical startups, most often at Funding Round and Series A stage. Most of the 15 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Providence Investment Company Limited invest in?
Providence Investment Company Limited typically joins rounds of $2.2M–$30M at Series B. These are whole funding-round sizes, not Providence Investment Company Limited's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Providence Investment Company Limited took part in.
When did Providence Investment Company Limited last invest?
The most recent investment recorded for Providence Investment Company Limited closed in Nov 2025. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
